Healthcare nonprofit Open Medicine Foundation (OMF) on Wednesday launched a large-scale international collaborative study to investigate the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or US FDA approved treatments available.
The company added that the Post-Acute Sequelae SARS-CoV-2 infection is also known as Long COVID or Post-COVID Syndrome. Up to 2.5m people in the US alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. The company's goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.
This USD5m, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world's top researchers and ME/CFS experts. The focus is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS.
Additionally, the federal government is now investing in Post-COVID research, with no focus on its connection to ME/CFS.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT